IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was founded by Derek Lionel Glendon Hill on November 28, 1995 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company